Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Ovid Therapeutics Inc.

Get SEC filing alerts via email and in your feed for Ovid Therapeutics Inc.

OVID

Ovid Therapeutics Inc.

About Ovid Therapeutics Inc.

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain conditions with unmet needs, including epilepsy and psychosis. Its pipeline features innovative therapies targeting neuronal hyperexcitability, such as GABA-AT inhibitors, KCC2 activators, and ROCK2 inhibitors. The company aims to deliver safer, more effective treatments for neurological and psychiatric disorders, leveraging strategic licensing, collaborations, and a scientific approach to address fundamental brain biology.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Ovid Therapeutics Inc.

1
1
Ovid Therapeutics Inc. Ovid Therapeutics Reports Q1 2026 Financial Results with Increased Net Loss and No Revenue

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Ovid Therapeutics Inc. Ovid Therapeutics Reports $17.4 Million Net Loss and $7.3 Million Revenue for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Ovid Therapeutics Inc. Ovid Therapeutics Reports Q3 2025 Revenue Decline and Net Loss Amid Increased Year-to-Date Revenue

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Ovid Therapeutics Inc. Ovid Therapeutics Reports $6.4M Revenue Growth Amid $14.9M Net Loss in Latest Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Ovid Therapeutics Inc. Ovid Therapeutics Reports Q1 2025 Financial Results with Revenue Decline and Reduced Losses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Ovid Therapeutics Inc. Ovid Therapeutics Reports $26.4 Million Net Loss for 2024, Improved from Previous Year

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Ovid Therapeutics Inc. Ovid Therapeutics Reports Modest Revenue Growth, Continued Net Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments